NOVARTIS has announced
that the Phase III head-to-head,
double blind, double dummy
LANTERN study has shown that
Ultibro Breezhaler demonstrated
superiority in lung function
compared to Seretide Accuhaler
in chronic obstructive pulmonary
disease (COPD).The above article was sent to subscribers in Pharmacy Daily's issue from 01 May 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 May 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.